Skip to content
Screener

Quest Diagnostics DGX Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
-$5.66M-28.3%

Other financials

Income statement

See full
Revenue$3.0B+10.2%
Gross profit$1.0B+8.9%
Operating income$459.0M+4.8%
Net income$320.0M+13.5%
EPS (diluted)$2.84+15.0%

Balance sheet

See full
Cash & equivalents$626.0M+96.2%
Total debt$6.4B0.0%
Total equity$7.5B+4.0%
Total assets$16.9B+6.1%

Cash flow

See full
Operating cash flow$597.0M+9.7%
CapEx$138.0M+27.8%
Free cash flow$459.0M+5.3%

Valuation

See full
Market cap$26.31B+31.9%
Enterprise value$32.06B+23.3%
P/E24.8×+3.8×
P/S2.3×+0.4×

Profitability

See full
Gross margin33.1%+0.1pp
Operating margin14.1%+0.1pp
Net margin9.2%+0.2pp
FCF margin11.7%0.0pp

Returns & leverage

See full
Return on equity14.4%+0.7pp
Debt / equity0.8×0.0×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Quest Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The source filing: Quest Diagnostics’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:16 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001022079-26-000070
Line itemJune 30,2026December 31,2025
Additional paid-in capital2,3742,381
Retained earnings10,3749,994
Accumulated other comprehensive loss(62)(27)
Treasury stock, at cost; 52 shares as of both June 30, 2026 and December 31, 2025(5,172)(5,180)
Total Quest Diagnostics stockholders’ equity7,5167,170
Noncontrolling interests30336
Total stockholders’ equity7,8197,206
Total liabilities and stockholders’ equity$16,939$16,225

Cover / Front Matter

FAQ

What is Quest Diagnostics's noncontrolling interests in subsidiaries?
Quest Diagnostics (DGX) reported noncontrolling interests in subsidiaries of $303M in Q2 2026.
How has Quest Diagnostics's noncontrolling interests in subsidiaries changed year-over-year?
Quest Diagnostics's noncontrolling interests in subsidiaries increased by 718.9% year-over-year, from $37M to $303M.
What is the long-term trend for Quest Diagnostics's noncontrolling interests in subsidiaries?
Over 5 years (2020 to 2025), Quest Diagnostics's noncontrolling interests in subsidiaries has grown at a -6.4% compound annual growth rate (CAGR), from $50M to $36M.
What does noncontrolling interests in subsidiaries mean?
This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.

Ask your AI about Quest Diagnostics's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude